English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Since the discovery of endothelin (ET, later ET -1), multiple receptors for the peptide have been described. Thus far, two of these, termed ETA and ETB, have been pharmacologically characterized and cloned (for review see 1). The ETAreceptor appears to be the predominant vascular smooth muscle receptor, and selectively binds to ET-1 over ET-3, resulting in vasoconstriction. The isopeptide nonselective ETB receptor is widely expressed (e.g. in

Haloemodins, a new class of endothelin-1 type B (ETB) receptor binding inhibitors.